Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Half-dose sugammadex for reversal of rocuronium-induced neuromuscular blockade
2013-002362-39Phase 4Active
- Sponsor
- Parc de Salut Mar
- Start
- Jul 2013
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of Sugammadex in neuromuscular block (NMB) (2 arms), sponsored by Parc de Salut Mar. Primary endpoint: Percentage of patients with successful antagonism of neuromuscular blockade using half-dose sugammadex. Started Jul 2013; status: active.
02
Drugs
Sugammadex
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on 2013-002362-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002362-39.